AGM/EGM Notice
Molbio Diagnostics Postal Ballot Advertisement
Molbio Diagnostics published newspaper advertisements regarding its proposed Postal Ballot Notice, remote e-voting facility and November 20, 2026 cut-off date.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Investor Presentation
Q2 FY27
Investor Presentation
Q1 FY27

Healthcare Equipment & Supplies
Medical Equipment & Supplies
17,599 Cr
Low Risk
66.89
60.46
1.03
12.22
1,686.50
925.80
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
5
Neutral
7
Bullish
2
Bearish
10
Neutral
19
Bullish
17
Bearish
5
Neutral
12
Bullish
15
Bearish
5
Neutral
12
Bullish
15
Bearish
5
Neutral
12
Bullish
15
Bearish
5
Neutral
12
Bullish
15
Molbio Diagnostics Ltd (MOLBIO) is currently trading at 1,497.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Molbio Diagnostics Limited develops and manufactures point-of-care diagnostic devices, molecular assays, reagents, X-ray equipment, and digital pathology solutions for public-health programs, laboratories, hospitals, and veterinary applications. Its flagship Truenat platform enables battery-operated molecular PCR testing in resource-limited settings, while the company operates manufacturing facilities across Goa, Bengaluru, and Visakhapatnam. H1 FY27 revenue was INR667 crore, broadly near the prior-year INR680 crore, but below internal expectations because government rate-contract renewal delayed shipments by approximately one month. Management stated that orders are now available and being dispatched, with the deferred activity expected to shift into the second half rather than disappear. Molbio Diagnostics Limited is transitioning from a predominantly TB-associated business into a broader diagnostics platform company. Hepatitis, HPV, HIV viral-load applications, veterinary testing, radiology, digital pathology, and three internally developed platforms—Truepoc, Trueamp, and Truecyte—create several potential growth vectors beyond the established Truenat opportunity. The company reported 559 devices and 94.7 lakh kits sold during H1 FY27, with exports contributing approximately INR120 crore. Despite OptraSCAN-related losses, collections improved, the company moved from net debt to net cash, and management maintained its 25% annual revenue-growth and 24%–25% EBITDA-margin guidance. A notable strategic shift is the planned entry into veterinary diagnostics, initially focused on companion animals and supported by radiology, rabies testing, and six additional assays expected around FY28. Molbio Diagnostics Limited is attempting to create a new point-of-care veterinary market rather than merely displace established molecular competitors.
Over the past 52 weeks, Molbio Diagnostics Ltd has traded between a low of ₹925.80 and a high of ₹1,686.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Molbio Diagnostics Ltd has a market capitalization of approximately 17,598.88. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Molbio Diagnostics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 66.89 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 17,598.88 Cr, Molbio Diagnostics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Molbio Diagnostics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Molbio Diagnostics Ltd is 66.89. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Molbio said a one-month delay in negotiating and renewing its government rate contract postponed order releases and invoicing. Management estimated that about Rs 100 crore that otherwise would have been invoiced in the first half shifted into the second half. It said the delay did not change the annual government procurement target.
Molbio expects its initial new veterinary products to reach the market in FY28. Management said two of the six assays beyond rabies are in development and testing, followed by initial data and analytical studies.
Molbio expects the initial CDSCO manufacturing-and-sale licensing process to take about four to five months. Management said studies were already under way during the Q2 fiscal 2027 earnings call. Approval remains pending, not completed.
Molbio reported H1 FY27 PAT of Rs 60.4 crore. That was Rs 22.5 crore lower than Rs 82.9 crore in H1 FY26, and the PAT margin declined to 8.9% from 12.2%.